Dr. Karen Wright, MD
Claim this profileDana-Farber Cancer Institute
Studies Brain Tumor
Studies Diffuse Intrinsic Pontine Glioma
4 reported clinical trials
6 drugs studied
Area of expertise
1Brain Tumor
RAS positive
RAF positive
MEK positive
2Diffuse Intrinsic Pontine Glioma
Stage IV
Affiliated Hospitals
Clinical Trials Karen Wright, MD is currently running
PEP-CMV Vaccine
for Pediatric Brain Tumor
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51. Funding Source - FDA OOPD
Recruiting1 award Phase 2
Dabrafenib + Trametinib
for Brain Tumors
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
Recruiting3 awards Phase 47 criteria
More about Karen Wright, MD
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Karen Wright, MD has experience with
- Tovorafenib/DAY101
- PTC596
- Radiotherapy
- PEP-CMV Vaccine
- Dabrafenib
- Trametinib
Breakdown of trials Karen Wright, MD has run
Brain Tumor
Diffuse Intrinsic Pontine Glioma
Low Grade Glioma
Medulloblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Karen Wright, MD specialize in?
Karen Wright, MD focuses on Brain Tumor and Diffuse Intrinsic Pontine Glioma. In particular, much of their work with Brain Tumor has involved RAS positive patients, or patients who are RAF positive.
Is Karen Wright, MD currently recruiting for clinical trials?
Yes, Karen Wright, MD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Karen Wright, MD has studied deeply?
Yes, Karen Wright, MD has studied treatments such as Tovorafenib/DAY101, PTC596, Radiotherapy.
What is the best way to schedule an appointment with Karen Wright, MD?
Apply for one of the trials that Karen Wright, MD is conducting.
What is the office address of Karen Wright, MD?
The office of Karen Wright, MD is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.